Halozyme Therapeutics to Acquire Elektrofi 

Halozyme Therapeutics, Inc. has entered into a definitive agreement to acquire Elektrofi, Inc., a biopharmaceutical company with a breakthrough ultra-high concentration microparticle technology for biologics, branded Hypercon.  

The transaction, which is comprised of an upfront payment of $750 million and up to three $50 million milestone payments contingent on three separate product regulatory approvals, was unanimously approved by the Boards of Directors of both Halozyme and Elektrofi. 

The Hypercon technology is a microparticle approach that enables high protein concentrations while maintaining syringeability, which is the ability to inject smoothly and easily. Hypercon enables biologic product formulation concentrations of 400-500 mg/ml, which can be up to 4 to 5 times higher than standard aqueous solution formulations for biologics today. The increased concentration reduces the volume of injection for the same dosage and will create more opportunities for at-home and HCP office delivery, including via small volume auto-injector or with Halozyme’s innovative high volume auto-injector. 

“With Elektrofi’s Hypercon technology, we are expanding and diversifying our drug delivery technology offerings to the biopharma industry and positioning Halozyme for continued long-term revenue growth through Elektrofi’s licensing, royalty revenue business model,” said Dr. Helen Torley, President and CEO of Halozyme. “We look forward to welcoming Elektrofi’s talented team as we embark on our next chapter of drug delivery innovation to continue to drive value for all of our stakeholders including our partners, patients, and shareholders.” 

Chase Coffman, CEO and Co-founder of Elektrofi, added, “Halozyme’s proven industry expertise and capabilities in developing drug delivery licensing businesses will advance our unique Hypercon technology, strengthen existing collaborations, support expansion into new partnerships and accelerate our commercialization strategy.” 

Other Pharma Industry Acquisitions 

Check out Contract Pharma’s Pharmaceutical Industry Mergers & Acquisitions Roundup.